Washington, DC 20006-5349
HELPLINE
SAVE THE DATE
June 23-25, 2011 in Washington, DC. For more information visit curemeso.org/symposium. Stay tuned…
CAR-T (Chimeric antigen receptor) cell therapy is a type of immunotherapy that uses a patient’s T cells to attack cancer cells. T cells are white
For patients with MPM (Malignant Pleural Mesothelioma), the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) as a first-line treatment when combined with
Mesothelioma has often been classified as a cancer that only affects older people, as the average age of diagnosis for pleural is 72 and peritoneal
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
